Clinical Immunobiology

临床免疫生物学

• 批准号: 7714120
• 负责人: THEODORE G KRONTIRIS
• 金额: $ 4.26万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2012-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7714120
• 关键词: Biological Assay; Biological Models; Budgets; Cancer Center; Cancer Center Support Grant; Cells; Certification; Cities; Clinical; Clinical Trials; Clinical Trials, Other; Correlative Study; Cost Savings; Development; Environment; Evolution; Fees; Funding; Future; Guidelines; Immune; Immune system; Immunobiology; Immunotherapy; Laboratories; Laboratory Study; Lead; Methods; Modality; Molecular; Operating System; Operative Surgical Procedures; Patients; Peer Review; Policies; Publications; Publishing; Reporting; Research; Research Design; Research Infrastructure; Research Personnel; Resource Sharing; Source; Standards of Weights and Measures; Technology; Therapeutic; Therapeutic Effect; Translational Research; Treatment Protocols; Treatment outcome; Validation; Work; base; design; improved; in vitro Model; insight; member; novel; programs

The long-term objective for the new Clinical Immunobiology Correlative Studies Laboratory (CICSL) is to develop into a comprehensive, cutting-edge correlative studies laboratory to support clinical trial and translational research efforts sponsored primarily by Cancer Center investigators at City of Hope. Long-term specific aims include i) continued development and implementation of novel immunological platforms and assays, identified either from external sources or internally, that will support, in a significant way, ongoing and future clinical trials; ii) continued expansion of user base to reflect support, in magnitude and diversity, of the majority of correlative assay needs of Cancer Center investigators; iii) continued evolution and implemention of laboratory operating policies and infrastructure to adhere to GLP practices and ultimately lead to CLIA certification of the laboratory. The principle objective of the laboratory is to develop and implement quantitative methods to evaluate the effect of novel therapies on a patient's immune system, and correlate those effects with treatment outcome to guide the rational development of efficacious therapeutic regimens. The research design and methods for the laboratory are to identify technology platforms that would be most useful and appropriate to evaluate the effect of therapeutic modalities on patients, and to develop assays based on those platforms that could be used to evaluate clinical trials sponsored by Cancer Center investigators. To that end, the laboratory has expertise and infrastructure to develop molecular, flowbased and cell-based assays. The laboratory operates under GLP guidelines, a fact that supports a high standard of operations. During the most recent 10-month reporting period, the CICSL shared resource was used by 13 Cancer Center members from all 5 programs. Peer-reviewed usage represented 79% of total usage. Annual budget for this core is $603,900, of which 47% is institutional funding, 28% is user fees, 15% is from other sources, and 10% ($60,100) is requested from the CCSG.

新的临床免疫生物学相关研究实验室（CICSL）的长期目标是 发展成为一个全面的，前沿的相关研究实验室，以支持临床试验， 主要由City of Hope的癌症中心研究人员赞助的转化研究工作。长期 具体目标包括：i）继续开发和实施新的免疫学平台， 从外部来源或内部确定的分析，将以重要的方式支持正在进行的 以及未来的临床试验; ii）持续扩大用户群，以反映支持的规模和多样性， 癌症中心研究人员的大多数相关测定需求; iii）持续的发展和 实施实验室操作政策和基础设施，以遵守GLP规范，并最终 实验室的CLIA认证。实验室的主要目标是开发和 实施定量方法来评估新疗法对患者免疫系统的影响，以及 将这些效应与治疗结果相关联，以指导合理开发有效的治疗方法， 养生法实验室的研究设计和方法是确定技术平台， 将是最有用和适当的，以评估治疗方式对患者的影响， 开发基于这些平台的检测方法，可用于评估癌症研究所赞助的临床试验。 中心调查员。为此，实验室拥有专业知识和基础设施， 和基于细胞的测定。实验室在GLP指导方针下运作，这一事实支持了高 操作标准。在最近10个月的报告期内，CICSL共享资源 来自所有5个项目的13名癌症中心成员使用。同行评审的使用占总数的79% 使用.这一核心的年度预算为603 900美元，其中47%为机构供资，28%为使用费，15%为非政府组织供资，20%为非政府组织供资。 来自其他来源，10%（60，100美元）来自CCSG。